826 Shares in Intuitive Surgical, Inc. $ISRG Bought by Kera Capital Partners Inc.

Key Points

• Kera Capital Partners Inc. has entered the market by acquiring 826 shares of Intuitive Surgical, Inc. (ISRG), valued at approximately $449,000.
• Intuitive Surgical's stock has seen significant interest from institutional investors, with 83.64% of the stock owned by these entities following large stakes purchased by firms like Nuveen LLC and GAMMA Investing LLC.
• Analysts have recently increased their price targets for ISRG, with estimates now ranging up to $599.00, reflecting a consensus rating of "Moderate Buy" among 20 analysts.

Kera Capital Partners Inc. acquired a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 826 shares of the medical equipment provider's stock, valued at approximately $449,000.

A number of other institutional investors have also made changes to their positions in ISRG. Nuveen LLC acquired a new stake in shares of Intuitive Surgical during the first quarter worth $1,715,899,000. GAMMA Investing LLC grew its stake in shares of Intuitive Surgical by 54,010.7% during the first quarter. GAMMA Investing LLC now owns 3,028,576 shares of the medical equipment provider's stock worth $14,999,630,000 after purchasing an additional 3,022,979 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Intuitive Surgical by 26.1% during the first quarter. Goldman Sachs Group Inc. now owns 2,819,666 shares of the medical equipment provider's stock worth $1,396,496,000 after purchasing an additional 584,375 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Intuitive Surgical by 20.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,393,951 shares of the medical equipment provider's stock worth $1,680,922,000 after purchasing an additional 566,979 shares during the period. Finally, Wellington Management Group LLP grew its stake in shares of Intuitive Surgical by 15.0% during the first quarter. Wellington Management Group LLP now owns 3,499,052 shares of the medical equipment provider's stock worth $1,732,975,000 after purchasing an additional 457,080 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Intuitive Surgical

In other news, EVP Myriam Curet sold 4,500 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the completion of the transaction, the executive vice president directly owned 353 shares of the company's stock, valued at $173,845.44. This represents a 92.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Amy L. Ladd sold 336 shares of the company's stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $470.11, for a total value of $157,956.96. Following the transaction, the director directly owned 1,074 shares of the company's stock, valued at $504,898.14. This represents a 23.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 45,224 shares of company stock valued at $21,716,492 over the last three months. Company insiders own 0.70% of the company's stock.

Analysts Set New Price Targets

A number of research firms have issued reports on ISRG. UBS Group boosted their target price on Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. Evercore ISI boosted their target price on Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Piper Sandler reissued an "overweight" rating and issued a $595.00 target price (up from $575.00) on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Wells Fargo & Company boosted their target price on Intuitive Surgical from $559.00 to $599.00 and gave the company an "overweight" rating in a research note on Wednesday, July 23rd. Finally, Erste Group Bank reissued a "hold" rating on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Thirteen research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $595.95.

Intuitive Surgical Price Performance

ISRG stock opened at $449.68 on Friday. The stock has a market capitalization of $161.20 billion, a P/E ratio of 62.72, a P/E/G ratio of 4.78 and a beta of 1.61. The business has a 50-day moving average of $485.67 and a 200-day moving average of $508.71. Intuitive Surgical, Inc. has a fifty-two week low of $425.00 and a fifty-two week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, topping the consensus estimate of $1.93 by $0.26. The company had revenue of $2.44 billion during the quarter, compared to analysts' expectations of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.Intuitive Surgical's revenue for the quarter was up 21.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.78 earnings per share. Equities analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.